The European CyberKnife Center Munich is celebrating its 5,000th patient treatment using the CyberKnife® System

   The European CyberKnife Center Munich is celebrating its 5,000th patient
                    treatment using the CyberKnife® System

Where experience and state-of-the-art technology meet

PR Newswire

SUNNYVALE, Calif., April 7, 2014

SUNNYVALE, Calif., April 7, 2014 /PRNewswire/ --Accuray Incorporated (Nasdaq:
ARAY) announced today that the European CyberKnife Center Munich-Grosshadern
(ECZM) has performed 5,000 CyberKnife® treatments since June 2005. The center
uses a CyberKnife M6™ System from the latest generation series, the most
advanced robotic radiosurgery system in the world. Patients of the center
benefit from a treatment option that offers enhanced stereotactic
radiosurgery/stereotactic body radiation therapy (SRS/SBRT): tumors are
treated non-invasively with precisely delivered high doses of radiation.

The European CyberKnife Center, in partnership with the University Hospital of
Munich-Großhadern, offers almost 10 years of experience with this
state-of-the-art technology. "The treatment with the CyberKnife System offers
a number of benefits compared to surgery: no anesthesia, no pain and minimal
side effects," explains Prof. Alexander Muacevic, who founded the treatment
center together with his colleague Prof. Berndt Wowra in 2005. The CyberKnife
System is used for tumors anywhere in the body. Prof. Muacevic added, "We
treat brain tumors as well as tumors in the spine, the lung, the liver, and
the prostate with good clinical outcomes. This remarkable technology is based
on an integration of the latest developments in the field of image guidance,
computer sciences and robotic radiation delivery."

The CyberKnife System features a compact linear accelerator mounted on a
robotic arm. It is the only system that automatically adjusts the beam
delivery to motion during treatment in real-time. This precision is essential
to deliver high doses to the target area while simultaneously minimizing
radiation exposure to surrounding healthy tissue and organs. The CyberKnife M6
System can deliver non-coplanar, non-isocentric beams from a wider number of
angles around the patient, with the ability to follow tumors in real-time
throughout the treatment. This provides clinicians the confidence to reduce
margins for every disease that is treatable with the CyberKnife System.

"Accuray is proud of the cooperation with the European CyberKnife Center. We
congratulate the European CyberKnife team on this tremendous achievement, and
are pleased our precise, innovative tumor treatments are available to patients
in such a highly experienced center," said Lionel Hadjadjeba, SVP Business
International & GM EIMEA, Accuray International.

About Accuray
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company that
develops, manufactures and sells precise, innovative treatment solutions that
set the standard of care with the aim of helping patients live longer, better
lives. The company's leading-edge technologies deliver the full range of
radiation therapy and radiosurgery treatments.

About the European CyberKnife Center, Germany
Besides the clinical and scientific cooperation with the Neurosurgical
Department and the Institute of Clinical Radiology of the University of
Munich, the CyberKnife Center Munich collaborates internationally with
colleagues around the world. Close partnerships exist with the University
Hospital Charite Berlin ( and the Stanford
University, California/ USA.

Furthermore a scientific partnership is maintained with the Institute of
Robotics and Cognitive Systems of the University Lübeck (Director: Professor
Dr. Schweikard) where essential parts of the CyberKnife System have been
developed (navigation software). Via the most modern telecommunication systems
special cases are discussed with other dedicated experts around the world.
Also, scientific projects are conducted on an international basis.Being part
of the Radiosurgery Society's ( Board of Directors we
put great effort in the development of internationally appreciated standards
for treatment, education and quality control.

Safe Harbor Statement
Statements made in this press release that are not statements of historical
fact are forward-looking statements and are subject to the "safe harbor"
provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements in this press release relate, but are not limited
to, the level of development of new technologies, clinical experience,
clinical applications, clinical results, patient experiences and outcomes, and
the company's leadership position in radiation oncology innovation and
technology. Forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially from expectations,
including risks detailed under the heading "Risk Factors" in the company's
report on Form 10-K filed on August 29, 2013, the company's report on Form
10-Q filed on February 7, 2014, and as updated periodically by the company's
other filings.

Forward-looking statements speak only as of the date the statements are made
and are based on information available to the company at the time those
statements are made and/or management's good faith belief as of that time with
respect to future events. Accuray assumes no obligation to update
forward-looking statements to reflect actual performance or results, changes
in assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities laws.
Accordingly, investors should not place undue reliance on any forward-looking

SOURCE Accuray Incorporated

Contact: Sancie Nakarat, Sr Marketing Communications Manager, Europe, Tel + 33
(0) 1 55 23 20 20,; Laura Scally, MSLGROUP, +1 (781)
Press spacebar to pause and continue. Press esc to stop.